SURUNKALI MIYELOID LEYKEMIYA BILAN BEMORLARDA TARGET TERAPIYANING PROGNOZI VA NATIJALARI

Authors

  • Anajan Gazxanovna Madasheva Samarqand davlat tibbiyot universiteti gematologiya kafedrasi, PhD, katta o‘qituvchi https://orcid.org/0009-0006-3080-1345
  • Feruza Xaydarovna Mamatkulova Samarqand davlat tibbiyot universiteti gematologiya kafedrasi assistenti https://orcid.org/0009-0000-5578-6424
  • Ozoda Sherzodovna Muxitdinova Samarqand davlat tibbiyot universiteti gematologiya kafedrasi, magistr rezidenti

DOI:

https://doi.org/10.5281/zenodo.24143817

Keywords:

chronic myeloid leukemia, targeted therapy, tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, bosutinib, clinical practice

Abstract

Chronic myeloid leukemia (CML) is a malignant hematopoietic neoplasm associated with a characteristic chromosomal abnormality known as the Philadelphia chromosome. A highly targeted treatment approach based on a distinct class of drugs — tyrosine kinase inhibitors (TKIs) — was developed for the treatment of CML, leading to improved disease outcomes. The goal of modern CML therapy is to achieve maximal reduction of the Ph-positive leukemic clone and minimize the risk of disease progression, while aiming for life expectancy comparable to that of the general population. Achieving a complete cytogenetic response (CCyR) and a major molecular response (MMR) represents an early favorable prognostic indicator of long-term progression-free survival during continuous therapy. Currently, TKIs are the mainstay of CML treatment and have demonstrated advantages over other therapeutic approaches. First- and second-line TKI therapies should be selected based on their efficacy and the lowest possible risk of adverse effects. Early assessment of treatment response, prevention of resistance development, and prompt transition to the most effective therapy in cases of suboptimal response should be the key principles of modern CML management. The aim of this study was to evaluate the efficacy of targeted therapy and its impact on the prognosis of chronic myeloid leukemia, as well as to investigate changes in these outcomes based on molecular genetic monitoring data.

References

1. Абдулкадыров, К. М., Бессмельцев, С. С., & Рукавицын, О. А. (1998). Хронический миелолейкоз. СпецЛит.

2. Абдулкадыров, К. М., Шуваев, В. А., & Мартынкевич, И. С. (2016). Миелопролиферативные новообразования. Литтерра.

3. Ben-Neriah, D. G., Mes-Masson, A. M., Witte, O. N., et al. (1986). The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 233(4760), 212–214. https://doi.org/10.1126/science.3460176

4. Talpaz, M., McCredie, K. B., Mavligit, G. M., et al. (1983). Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62(3), 689–692.

5. Druker, B. J., Tamura, S., Buchdunger, E., et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2(5), 561–566. https://doi.org/10.1038/

6. Туркина, А. Г., Зарицкий, А. Ю., Шуваев, В. А., et al. (2017). Клинические рекомендации по диагностике и лечению хронического миелолейкоза. Клиническая онкогематология. Фундаментальные исследования и клиническая практика, 10(3), 294–316. https://doi.org/10.21320/2500-2139-2017-10-3-294-316

7. Иматиниб (Imatinib): инструкция, применение и формула. (2014). Регистр лекарственных средств России.

8. Branford, S., Lawrence, R., Grigg, A., et al. (2008). Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. Blood, 112(11).

9. Redaelli, S., Piazza, R., Rostagno, R., et al. (2009). Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. Journal of Clinical Oncology, 27(3), 469–471. https://doi.org/10.1200/JCO.2008.19.8853

10. Jabbour, E., Cortes, J., Giles, F., et al. (2007). Drug evaluation: Nilotinib — a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs, 10(7), 468–479.

11. Mamatkulova, F. X., Mamatova, N. T., & Ruziboeva, O. N. (n.d.). Prevention of Anemia in Patients With Tuberculosis. The American Journal of Medical Sciences and Pharmaceutical Research, 2(11), 62–65. https://doi.org/10.37547/TAJMSPR/Volume02Issue11-11

12. Makhmonov, L. S., Mamatkulova, F. Kh., Berdiyarova, M. B., & Shomurodov, K. E. (n.d.). The Main Causes of Anemia in Iron and Vitamin B12 Deficiency Associated With Helicobacter pylori.

13. Makhmonov, L. S., Mamatkulova, F. Kh., Kholturaeva, D. F., & Muyiddinov, Z. Z. (2022). Importance of Detection of Hepsidine and Interleukins in Iron Deficiency Anemia. Asian Journal of Multidimensional Research, 11.

14. Dadajanov, U. D., & Mamatkulova, F. Kh. (2020). R. Oyjamol N. Features of Thrombophilia in COVID-19. European Journal of Molecular & Clinical Medicine, 7.

15. Mamatkulova Feruza Khaydarovna, Akhmedov Husan Isrofilovich, Abdiev Kattabek Makhmatovich. Essential Thrombocythemia — Principal Analysis in Children and Adolescents. (2023). Journal of Intellectual Property and Human Rights, 2, 23–29.

16. Maxmonov, L. S., Rizayev, J. A., & Gadayev, A. G. (2021). Helicobacter pylori va uning temir hamda vitamin B12 tanqisligi kamqonligi yuzaga kelishidagi ahamiyati. Проблемы биологии и медицины, (5), 215–218.

17. Ruziboeva, O. N., Abdiev, K. M., Madasheva, A. G., & Mamatkulova, F. K. (n.d.). Modern Methods of Treatment of Hemostasis Disorders in Patients With Rheumatoid Arthritis. Ученый XXI века, (78), 8–11.

18. Gadayev, A. G., Maxmonov, L. S., & Mamatqulova, F. X. (2022). Helicobacter pylori bilan assotsiyalangan temir va vitamin B12 tanqisligi kamqonliklarida yallig‘lanish sitokinlarining ayrim laborator ko‘rsatkichlar bilan o‘zaro bog‘liqligi. Biologiya va tibbiyot muammolari, (5).

Downloads

Published

2026-11-11

How to Cite

1.
Madasheva AG, Mamatkulova FX, Muxitdinova OS. SURUNKALI MIYELOID LEYKEMIYA BILAN BEMORLARDA TARGET TERAPIYANING PROGNOZI VA NATIJALARI. TTI [Internet]. 2026 Nov. 11 [cited 2026 Nov. 17];2(11):226-30. Available from: https://tibbiyot-talimi-va-innovatsiyalari.uz/index.php/TTI/article/view/265
Vol. 2 No. 11 (2026): Journal of "Medical Education and Innovations"